RVL Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2022	2021	2020	2019	2018	2017	2016
Market Capitalization	0	111	90	258	363	407	-	-
Market Cap Growth	-	23.47%	-65.12%	-28.96%	-10.82%	-	-	-
Enterprise Value	39	124	97	365	540	605	286	309
PE Ratio	-0.81	-2.15	-1.38	-3.24	-1.34	-3.71	-	-
PS Ratio	1.51	2.23	5.14	9.29	1.51	1.54	-	-
PB Ratio	0.00	2.17	1.17	2.75	3.16	1.06	-	-
P/FCF Ratio	-1.20	-2.95	-1.59	17.78	12.28	12.18	-	-
P/OCF Ratio	-1.25	-2.94	-1.64	14.66	10.81	10.84	-	-
EV/Sales Ratio	1.06	2.49	5.55	13.16	2.25	2.29	1.16	1.42
EV/EBITDA Ratio	-1.59	-2.43	-1.85	-6.06	-2.43	-37.12	-28.20	-37.31
EV/EBIT Ratio	-1.58	-2.41	-1.60	-4.50	-1.93	-6.18	-5.05	-9.71
EV/FCF Ratio	-2.03	-3.29	-1.72	25.19	18.29	18.10	5.61	-5.27
Debt / Equity Ratio	3.56	1.13	0.62	2.36	2.38	0.70	0.74	0.71
Debt / EBITDA Ratio	-0.97	-1.13	-0.91	-3.68	-1.23	-16.49	-31.63	-39.67
Debt / FCF Ratio	-1.25	-1.53	-0.84	15.28	9.25	8.04	6.30	-5.60
Quick Ratio	0.31	2.41	2.12	2.10	1.84	1.12	0.58	0.54
Current Ratio	0.38	2.89	2.95	3.10	2.27	1.51	0.92	0.80
Asset Turnover	0.31	0.36	0.07	0.06	0.40	0.31	0.26	-
Interest Coverage	-7.05	-203.40	-15.08	-19.85	-15.36	-4.71	-1.95	-1.58
Return on Equity (ROE)	-155.20%	-83.50%	-91.10%	-61.30%	-121.00%	-26.80%	-9.10%	-
Return on Assets (ROA)	-56.80%	-37.40%	-27.50%	-18.30%	-45.60%	-12.80%	-4.30%	-
Return on Capital (ROIC)	-95.04%	-54.33%	-66.53%	-28.74%	-72.34%	-15.10%	-6.88%	-4.04%
Earnings Yield	-61500900.90%	-46.55%	-72.18%	-30.87%	-74.64%	-26.95%	-	-
FCF Yield	-41923423.42%	-33.93%	-62.73%	5.63%	8.14%	8.21%	-	-
Buyback Yield / Dilution	-18.89%	-33.32%	-11.05%	-15.82%	-15.66%	-5.65%	-4184.89%	-
Total Shareholder Return	-18.89%	-33.32%	-11.05%	-15.82%	-15.66%	-5.65%	-4184.89%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).